Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Beuzeboc

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
The New England Journal of Medicine|October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial CarcinomaMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
JAMA Oncology|February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical TrialStéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trialKarim Fizazi, Francois Lesaunier, Remy Delva, et al.
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Nature Communications|October 31, 2024
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer PatientsAnne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
The Lancet. Oncology|June 2, 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trialKarim Fizazi, Laura Faivre, François Lesaunier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2026
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12Cécile Vicier, Farah Erdogan, Nedjla Allouache, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
The Lancet. Oncology|January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialGwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
The New England Journal of Medicine|October 23, 2023
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial CarcinomaMichiel S van der Heijden, Guru Sonpavde, Thomas Powles, et al.
JAMA Oncology|February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical TrialStéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trialKarim Fizazi, Francois Lesaunier, Remy Delva, et al.
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Nature Communications|October 31, 2024
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer PatientsAnne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
The Lancet. Oncology|June 2, 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trialKarim Fizazi, Laura Faivre, François Lesaunier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2026
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12Cécile Vicier, Farah Erdogan, Nedjla Allouache, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
The Lancet. Oncology|January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialGwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
Pageof 13